Producción CyT
Artículo
Autoría
Bruni, Sofia
;
MERCOGLIANO, MARIA FLORENCIA
;
Mauro, Florencia Luciana
;
Cordo Russo, Rosalia Ines
;
SCHILLACI, ROXANA
Fecha
2023
Editorial y Lugar de Edición
Frontiers Media S.A.
Revista
Frontiers in Oncology,
vol. 13
(pp. 1-25)
Frontiers Media S.A.
Resumen
Información suministrada por el agente en
SIGEVA
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving posi...
Immunotherapy has changed the course of cancer treatment. The initial steps were made through tumor-specific antibodies that guided the setup of an antitumor immune response. A new and successful generation of antibodies are designed to target immune checkpoint molecules aimed to reinvigorate the antitumor immune response. The cellular counterpart is the adoptive cell therapy, where specific immune cells are expanded or engineered to target cancer cells. In all cases, the key for achieving positive clinical resolutions rests upon the access of immune cells to the tumor. In this review, we focus on how the tumor microenvironment architecture, including stromal cells, immunosuppressive cells and extracellular matrix, protects tumor cells from an immune attack leading to immunotherapy resistance, and on the available strategies to tackle immune evasion.
Ver más
Ver menos
Palabras Clave
EXTRACELLULAR MATRIXTUMOR INFILTRATING LYMPHOCYTES (TILS)PHYSICAL BARRIERTUMOR-ASSOCIATED VASCULATUREMYELOID CELLSTUMOR-ASSOCIATED MACROPHAGE (TAMS)IMMUNE EXCLUSIONTUMOR MICROENVIRONMENT
Descargue o solicite el texto completo